

PredicineBEACON™

CLIA Validated Tissue-Agnostic, Personalized, Actionable MRD Assay

Sensitive Minimal Residual Disease (MRD) detection not limited by baseline tissue sample availability

50


Up to 50 personalized mutations

500

Actionable and hotspot mutations tracked

$\geq 0.005\%$


Tumor Fraction



Methods and Reporting

- Flexibility in baseline profiling: tissue or liquid biopsy (including blood, plasma, and urine)
- Sensitive MRD detection: limit of detection as low as 0.005% tumor fraction based on 30 ng cfDNA input, when personalized panel contains 50 mutations
- Includes genome-wide copy number changes including copy number reductions
- Longitudinally tracks up to 50 personalized mutations
- Includes analysis of 500 actionable and hotspot mutations

Workflow



PredicineBEACON™ addresses the challenges faced by conventional MRD assays

- Tissue agnostic solution: Baseline analysis can be obtained via blood, urine, or tissue
- High sensitivity: Ability to identify alterations missed by less sensitive assays
- Multidimensional: Detects changes including single nucleotide variants (SNVs), copy number variations (CNVs), and DNA rearrangements
- Actionable MRD result: Upon recurrence, actionable and hotspot mutation analysis can provide clinically relevant information to guide treatment decisions

Product Details



Baseline Profiling
Blood Urine



Multi-Dimensional MRD Detection
SNVs, CNVs, & DNA rearrangements





High Sensitivity
*0.005% Tumor Fraction
Limit of Detection*



Actionable MRD
*500 Actionable and Hotspot
Mutations*


Case Study 1: Tissue-free, urine-informed MRD in neoadjuvant MIBC

Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer¹



Case Study 2: Tissue-free, blood-informed MRD in clinical trial

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation²



¹Clin Cancer Res. 2023 Aug 3;CCR-23-0513 ²N Engl J Med 2023;389:710-21